Not found

Adriana E. Rosato, PhD

Associate Professor of Pathology and Genomic Medicine, Academic Institute
Associate Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Research Lab

After receiving her PhD in microbiology from the University of Paris, XI, in Paris, France, Dr. Rosato completed a postdoctoral fellowship in microbiology and infectious diseases at the University of Southern California and Children’s Hospital Los Angeles. She then completed a second fellowship at Virginia Commonwealth University in Richmond, VA, where she was the recipient of a prestigious National Research Service Award from the National Institutes of Health. Dr. Rosato remained at Virginia Commonwealth University after her postdoctoral training and became an assistant professor in the Department of Internal Medicine, Division of Infectious Diseases. She earned numerous honors while there, including the Faculty Award for Distinguished Research, and three faculty awards from the American Society of Microbiology for her mentoring of minority trainees. Dr. Rosato joined the Center for Molecular and Translational Human Infectious Diseases Research at the Houston Methodist Research Institute in 2010.

Description of Research

Multidrug resistant pathogens of clinical interests including , MRSA ( methicillin resistant S. aureus ) E.coli and Klebsiella pneumoniae.

My works in Infectious Diseases have extended for more than 24 years covering both aspects clinical, basic the translational aspects of related diseases. I have been conducting clinical and basic research on antimicrobials and multidrug-resistant (MDR) Gram-negative and Gram-positive bacterial pathogens to which treatment options are limited. My activities include as a group leader, pre-clinical and correlative clinical studies, writing protocols, presenting at scientific meetings and conferences developing collaborative relationships. I have a great deal of expertise in microbiology testing, molecular biology, diagnostics, genomic, transcriptomic analysis and in-vivo models. Moreover, working in close collaboration as advisor consultant of pharmaceutical companies/drug discovery, NIH-NIAID, and WHO division antimicrobial resistance. I am and have been involved in the discussion and decision of funding of USA and European agencies of clinical protocols. In addition, I have been contributing to the identification of antibacterial approaches and their execution, trained in areas of GCP, clinical trials, and CRO relationships. This extended experience has also helped me to grow as a scientist, mentor, and team leader, and making me better suited for the tasks as the evolution in the field requires.

Description of Research
Dr. Rosato's laboratory conducts translational research involving multidrug-resistant bacteria.  Dr. Rosato's laboratory aim to identify the molecular genetic causes of drug resistance in MRSA. Data from these investigations could identify new therapeutic targets and aid in the development of novel antimicrobial agents. Her laboratory uses molecular biology techniques to understand the genetic basis of antimicrobial resistance and resistance gene spread among S. aureus cells.


Education & Training

PhD, University of Paris XII
MSc, Institut Pasteur
MS, University of San Luis

Identification and molecular epidemiology of methicillin resistant Staphylococcus pseudintermedius strains isolated from canine clinical samples in Argentina
Gagetti, P, Wattam, AR, Giacoboni, G, De Paulis, A, Bertona, E, Corso, A & Rosato, AE 2019, BMC Veterinary Research, vol. 15, no. 1, 264.

VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Infection
Taglialegna, A, Varela, MC, Rosato, RR & Rosato, AE 2019, mSphere, vol. 4, no. 1.

Genetic diversity of KPC-producing Escherichia coli, klebsiella oxytoca, serratia marcescens, and citrobacter freundii isolates from Argentina
De Belder, D, Lucero, C, Rapoport, M, Rosato, A, Faccone, D, Petroni, A, Pasteran, F, Albornoz, E, Corso, A & Gomez, SA 2018, Microbial drug resistance (Larchmont, N.Y.), vol. 24, no. 7, pp. 958-965.

Activity of telavancin against staphylococcus aureus isolates, including those with decreased susceptibility to ceftaroline, from cystic fibrosis patients
Roch, M, Varela, MC, Taglialegna, A, Rose, WE & Rosato, AE 2018, Antimicrobial agents and chemotherapy, vol. 62, no. 9, e00956-18.

Combination antibiotic exposure selectively alters the development of vancomycin intermediate resistance in staphylococcus aureus
Zheng, X, Berti, AD, McCrone, S, Roch, M, Rosato, AE, Rose, WE & Chen, B 2018, Antimicrobial agents and chemotherapy, vol. 62, no. 2, e02100-17.

Daptomycin resistance in clinical MRSA strains is associated with a high biological fitness cost
Roch, M, Gagetti, P, Davis, J, Ceriana, P, Errecalde, L, Corso, A & Rosato, AE 2017, Frontiers in Microbiology, vol. 8, no. DEC, 2303.

Molecular bases determining daptomycin resistance-mediated resensitization to ß-lactams (seesaw effect) in methicillin-resistant Staphylococcus aureus
Renzoni, A, Kelley, WL, Rosato, RR, Martinez, MP, Roch, M, Fatouraei, M, Haeusser, DP, Margolin, W, Fenn, S, Turner, RD, Foster, SJ & Rosato, AE 2017, Antimicrobial agents and chemotherapy, vol. 61, no. 1, e01634-16.

Modeling meropenem treatment, alone and in combination with daptomycin, for KPC-producing Klebsiella pneumoniae strains with unusually low carbapenem MICs
Gagetti, P, Pasteran, F, Martinez, MP, Fatouraei, M, Gu, J, Fernandez, R, Paz, L, Rose, WE, Corso, A & Rosato, AE 2016, Antimicrobial agents and chemotherapy, vol. 60, no. 8, pp. 5047-5050.

The staphylococcus aureus chaperone PrsA is a new auxiliary factor of oxacillin resistance affecting penicillin-binding protein 2A
Jousselin, A, Manzano, C, Biette, A, Reed, P, Pinho, MG, Rosato, AE, Kelley, WL & Renzoni, A 2016, Antimicrobial agents and chemotherapy, vol. 60, no. 3, pp. 1656-1666.

Impact of efflux in the development of multidrug resistance phenotypes in Staphylococcus aureus
Costa, SS, Viveiros, M, Rosato, AE, Melo-Cristino, J & Couto, I 2015, BMC microbiology, vol. 15.

Iron- and hemin-dependent gene expression of Porphyromonas gingivalis
Anaya-Bergman, C, Rosato, AE & Lewis, JP 2015, Molecular Oral Microbiology, vol. 30, no. 1, pp. 39-61.

PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates
Long, SW, Olsen, RJ, Mehta, SC, Palzkill, T, Cernoch, PL, Perez, KK, Musick, WL, Rosato, AE & Musser, JM 2014, Antimicrobial agents and chemotherapy, vol. 58, no. 11, pp. 6668-6674.

Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance
Fernandez, R, Paz, LI, Rosato, RR & Rosato, AE 2014, Antimicrobial agents and chemotherapy, vol. 58, no. 10, pp. 5736-5746.

TCA cycle-mediated generation of ROS is a key mediator for HeR-MRSA survival under ß-lactam antibiotic exposure
Rosato, RR, Fernandez, R, Paz, LI, Singh, CR & Rosato, AE 2014, PLoS ONE, vol. 9, no. 6, e99605.

Staphylococcal phenotypes induced by naturally occurring and synthetic membrane-interactive polyphenolic ß-lactam resistance modifiers
Palacios, L, Rosado, H, Micol, V, Rosato, AE, Bernal, P, Arroyo, R, Grounds, H, Anderson, JC, Stabler, RA & Taylor, PW 2014, PLoS ONE, vol. 9, no. 4, e93830.

Identification of point mutations in clinical staphylococcus aureus strains that produce small-colony variants auxotrophic for menadione
Dean, MA, Olsen, RJ, Long, SW, Rosato, AE & Musser, JM 2014, Infection and Immunity, vol. 82, no. 4, pp. 1600-1605.

Exposure of Clinical MRSA Heterogeneous Strains to ß-Lactams Redirects Metabolism to Optimize Energy Production through the TCA Cycle
Keaton, MA, Rosato, RR, Plata, KB, Singh, CR & Rosato, AE 2013, PLoS ONE, vol. 8, no. 8, e71025.

Targeting of PBP1 by ß-lactams Determines recA/SOS Response Activation in Heterogeneous MRSA Clinical Strains
Plata, KB, Riosa, S, Singh, CR, Rosato, RR & Rosato, AE 2013, PLoS ONE, vol. 8, no. 4, e61083.

ß-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives
Mehta, S, Singh, C, Plata, KB, Chanda, PK, Paul, A, Riosa, S, Rosato, RR & Rosato, AE 2012, Antimicrobial agents and chemotherapy, vol. 56, no. 12, pp. 6192-6200.

A crossover trial of antimicrobial scrubs to reduce methicillin-resistant Staphylococcus aureus burden on healthcare worker apparel
Bearman, GML, Rosato, AE, Elam, K, Sanogo, K, Stevens, MP, Sessler, CN & Wenzel, RP 2012, Infection Control and Hospital Epidemiology, vol. 33, no. 3, pp. 268-275.

Live Chat Available